Johnson&Johnson in the news

RBC Capital maintained an Outperform rating on Johnson & Johnson with a $290 price target, citing strong performance in Innovative Medicines and strategic focus after divesting its consumer business.

Johnson & Johnson's dividend is gaining renewed investor interest due to its consistent payouts and the defensive nature of its healthcare business amidst shifting Federal Reserve rate expectations.

A new survey found that most women do not associate menopause with changes in eye health, leading many to not seek professional help for symptoms like dry eyes or blurry vision.

Johnson & Johnson reported sustained skin clearance with its oral drug ICOTYDE for plaque psoriasis patients over two years, showing high efficacy in challenging body areas and a consistent safety profile.

Johnson & Johnson's ICOTYDE® (icotrokinra) demonstrates sustained efficacy and safety for two years in treating plaque psoriasis, including difficult-to-treat areas like the scalp and genitals.

Johnson & Johnson's stock outperformed Medtronic's over the past decade due to its consumer healthcare business spinoff, a strategy Medtronic is now emulating with its diabetes unit.

Johnson & Johnson recently increased its quarterly payout, extending a six-decade streak of dividend raises, and is actively restructuring its diversified medical enterprise.

A Massachusetts jury ruled in favor of Johnson & Johnson in a talcum powder lawsuit, finding no causation for cancer but noting the product should have had a warning label.

Johnson & Johnson maintains its stock value through a strong pharmaceutical pipeline, innovative medical devices like the Ottava robotic-assisted surgery system, and a robust, long-standing dividend program.

Johnson & Johnson held steady in a growth-led market, bolstered by positive clinical trial updates for Imaavy and Tremfya, reinforcing its strong dividend history and robust pipeline.

Johnson & Johnson's stock has surged 96.4% in five years, raising questions about its current valuation against projected cash flows, despite strong clinical data for new therapies suggesting potential undervaluation according to a DCF model.

Johnson & Johnson anticipates in-line sales but an earnings miss for Q3 fiscal 2027, driven by IPR&D dilution, while projecting 6% revenue growth and focusing on new product launches and strategic acquisitions.

Johnson & Johnson reported strong second-quarter 2026 sales growth, driven by new drug performance, and raised its full-year financial guidance.

Johnson & Johnson is set to report Q3 results, following strong Q2 revenue growth and positive clinical trial results for a multiple myeloma treatment, despite a high P/E ratio.

Johnson & Johnson reported positive two-year clinical trial results for IMAAVY in adolescents with generalized myasthenia gravis and favorable outcomes for adults who switched to the therapy.

Bank of America increased its peak sales forecast for Icotyde to $4.5 billion, while also raising its price target for the company.

Johnson & Johnson continues its decades-long streak of increasing quarterly cash distributions, supported by its diversified healthcare business.

Johnson & Johnson CEO Joaquin Duato is joining PepsiCo's board of directors, bringing his extensive experience in strategic transformation and innovation.

Johnson & Johnson experienced net ETF selling on September 24, amounting to $49.1 million, following two days of net inflows.

Johnson & Johnson's Tremfya showed positive Phase 4 results for psoriatic arthritis, supporting growth as legacy product Stelara faces declining sales.